Study published in Neuro-Oncology shows brain tumor eradication and prolonged survival
Study conducted in mice treated with Toca 511 and 5-FC
2012-02-06
(Press-News.org) SAN DIEGO -- Tocagen Inc. today announced the publication of data showing the company's investigational treatment for high grade glioma eradicates brain tumors and provides a dramatic survival benefit in mouse models of glioblastoma. Almost all mice receiving the top dose of Toca 511 followed by 5-FC were still alive at 180 days, which was the termination date for the experiment, whereas all control mice died by day 43. The article was published today in the February issue of the Neuro-Oncology journal.
"After administration of Toca 511, the efficiency and specificity of viral spread through the tumor in an immune-competent animal model was impressive," said John Coffin, Ph.D., American Cancer Society Professor at the Sackler School of Biomedical Sciences at Tufts University and Special Advisor to the Director, HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute. "As a career retrovirologist and advisor to the scientists at Tocagen, I am pleased to see the progress they have achieved with their retroviral replicating vector technology, and I look forward to seeing how this approach translates in humans with advanced cancer."
The results published in Neuro-Oncology showed that Toca 511 delivers a pro-drug activating gene to tumor cells where it converts the pro-drug 5-FC (flucytosine) into the anti-cancer drug 5-fluorouracil. Treatment with the high doses of Toca 511 resulted in elimination of tumors in most animals after dosing with 5-FC. The combination treatment of Toca 511 and 5-FC was well tolerated and did not cause toxicity over the course of the six month treatment protocol.
"Because of the invasive nature of glioblastoma, cancer cells are typically left behind after surgery, even with a 'complete' resection, making tumor re-growth almost inevitable," said Santosh Kesari, M.D., Ph.D., director of Neuro-Oncology in the Moores Cancer Center and in the Department of Neurosciences at the University of California, San Diego, one of the investigators in the Toca 511 clinical study. "There is an urgent need for new treatments that can eliminate residual cancer cells in patients with glioblastoma and other invasive gliomas. These preclinical results are very promising and provided the support for initiating human clinical trials of Toca 511."
About Toca 511 & Toca FC
The combination of Toca 511 (vocimagene amiretrorepvec), for injection & Toca FC (flucytosine), extended-release tablets is being investigated at leading centers across the US in clinical studies in patients with recurrent high grade glioma, including glioblastoma multiforme (GBM). Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a prodrug activator gene called cytosine deaminase (CD) selectively to cancer cells. After allowing time for Toca 511 to spread through the tumor, those cancer cells expressing the CD gene can convert the anti-biotic drug flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). In these studies, patients receive a single administration of Toca 511 at the time of surgery (craniotomy or biopsy) followed by multiple cycles of oral Toca FC.
###
About Tocagen
Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene transfer products for the treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511, the company's lead investigational product candidate, is being evaluated in clinical trials in patients with recurrent high grade glioma (such as glioblastoma multiforme). Tocagen has received grant support from leading brain cancer foundations including, Accelerate Brain Cancer Cure (ABC2), the American Brain Tumor Association (ABTA), and the National Brain Tumor Society (NBTS). For more information about Tocagen or Toca 511 please visit http://www.tocagen.com or http://www.clinicaltrials.gov.
ELSE PRESS RELEASES FROM THIS DATE:
2012-02-06
Los Angeles, CA (February 3, 2012) As a brand new year gets underway, people all over America are resolving to better manage their weight and have a more healthy 2012. According to a new study, those starting new weight loss programs may be surprised to find out that both location and level of experience may influence their success. A recent article published in The Journal of Black Psychology (a journal from the Association of Black Psychologists, published by SAGE) finds that African American women beginning a new group weight loss program are more successful if they ...
2012-02-06
Prairie lands in Fort Bend County continue to be the natural choice for new-home communities. Beazer Homes and Taylor Morrison have joined forces to develop Churchill Farms, a 209-acre community in Fulshear, a small town in the greater Katy area west of Houston. Model home construction and presales will begin in February.
Churchill Farms will have three model parks to showcase Beazer Homes and Taylor Morrison product lines available in 50-, 60- and 70-ft. sections. Both builders are introducing new floor plans at Churchill Farms. Some of the models will open in mid-April ...
2012-02-06
La Jolla, CA---- One of the big mysteries in biology is why cells age. Now scientists at the Salk Institute for Biological Studies report that they have discovered a weakness in a component of brain cells that may explain how the aging process occurs in the brain.
The scientists discovered that certain proteins, called extremely long-lived proteins (ELLPs), which are found on the surface of the nucleus of neurons, have a remarkably long lifespan.
While the lifespan of most proteins totals two days or less, the Salk Institute researchers identified ELLPs in the rat ...
2012-02-06
The world of SEO may be highly lucrative for those that are ahead, but the competition behind the scenes can become a nightmare. Not only does every company have to deal with problems that arise from the clients, they must also manage their SEO team to keep up with all of the latest trends and relentless advancements in search engine optimization. The answer to these problems may be SEO reseller services from the top SEO company in Los Angeles, Avital Web.
Building that base of clients may seem like the easy part once an SEO company is up to speed. Companies are required ...
2012-02-06
PORTLAND, Ore. — A new way of opening blocked arteries in the brain using a removable stent system in people suffering strokes brought remarkably positive results in how those patients recovered from the strokes, according to a study presented this morning at the American Stroke Association's annual conference in New Orleans.
The interventional procedure was performed on more than 140 stroke patients at 18 medical centers throughout the United States. Stroke specialists at Oregon Health & Science University treated the most patients of any medical center in the country, ...
2012-02-06
Sequencing a patient's entire genome to discover the source of his or her disease is not routine – yet. But geneticists are getting close.
A case report, published this week in the American Journal of Human Genetics, shows how researchers can combine a simple blood test with an "executive summary" scan of the genome to diagnose a type of severe metabolic disease.
Researchers at Emory University School of Medicine and Sanford-Burnham Medical Research Institute used "whole-exome sequencing" to find the mutations causing a glycosylation disorder in a boy born in 2004. ...
2012-02-06
With major gaming events, national holidays, and sunny weather just around the corner, the California Office of Traffic Safety is now paying out huge sums to curb drinking and driving ("California Traffic Deaths Drop For Fifth Consecutive Year"). When all it takes is a single drink to be over the legal limit, this means that countless drivers in Southern California are going to be facing a driving under the influence charges this upcoming year. Amir Soleimanian, Beverly Hills DUI attorney, offers legal assistance for those drivers charged with DUI who want to ...
2012-02-06
Clarksburg, MD—Two different research groups have independently made the same important discoveries on how Alzheimer's disease spreads in the brain, according to a February 2 New York Times story. The groups' findings have the potential to give us a much more sophisticated understanding of what goes wrong in Alzheimer's disease and, more importantly, what can be done to prevent or repair damage in the brain.
The Times reported on the research teams of Bradley T. Hyman, MD, Ph.D., at Massachusetts General Hospital in Boston, and Karen E. Duff, Ph.D., of Columbia University ...
2012-02-06
When a friend tells you she had a rough day, do you feel sandpaper under your fingers? The brain may be replaying sensory experiences to help understand common metaphors, new research suggests.
Linguists and psychologists have debated how much the parts of the brain that mediate direct sensory experience are involved in understanding metaphors. George Lakoff and Mark Johnson, in their landmark work 'Metaphors we live by', pointed out that our daily language is full of metaphors, some of which are so familiar (like "rough day") that they may not seem especially novel or ...
2012-02-06
DETROIT – Henry Ford Hospital researchers have identified for the first time two molecules that hold promise as a biomarker for measuring cartilage damage associated with osteoarthritis.
Researchers say the concentration of two molecules called non-coding RNAs in blood were associated with mild cartilage damage in 30 patients who were one year removed from reconstruction surgery to repair an anterior cruciate ligament, or ACL, injury.
The findings are described as significant in the ongoing and tedious search of biomarkers for osteoarthritis, the most common form of ...
LAST 30 PRESS RELEASES:
[Press-News.org] Study published in Neuro-Oncology shows brain tumor eradication and prolonged survival
Study conducted in mice treated with Toca 511 and 5-FC
